| Donepezil |
II-1065/21.11.2007 |
YASNAL, Film coated tablet, 5, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
52.81 |
10.56 |
63.37 |
4% |
2.11 |
54.92 |
10.98 |
65.9 |
16% |
8.45 |
63.37 |
12.67 |
76.04 |
|
КЦ-326/28.11.2008 |
30.12.2008 |
30.12.2008 |
Неактивен |
1725 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22107.16 |
4421.43 |
26528.59 |
4% |
10 |
22117.16 |
4423.43 |
26540.59 |
16% |
25 |
22142.16 |
4428.43 |
26570.59 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017; НСР-17766/17.01.2019 |
01.02.2019 |
02.02.2019 |
Активен |
2252 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg), mg, Pack: 1vial |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
22452.93 |
4490.59 |
26943.52 |
4% |
10 |
22462.93 |
4492.59 |
26955.52 |
16% |
25 |
22487.93 |
4497.59 |
26985.52 |
|
НСР-8218/22.02.2016; НСР-12577/05.05.2017 |
20.05.2017 |
02.06.2017 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
5613.23 |
1122.65 |
6735.88 |
4% |
10 |
5623.23 |
1124.65 |
6747.88 |
16% |
25 |
5648.23 |
1129.65 |
6777.88 |
|
НСР-8219/22.02.2016; НСР-12576/05.05.2017 |
20.05.2017 |
02.06.2017 |
Активен |
2253 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6223.82 |
1244.76 |
7468.58 |
4% |
10 |
6233.82 |
1246.76 |
7480.58 |
16% |
25 |
6258.82 |
1251.76 |
7510.58 |
|
НСР-8219/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
24895.27 |
4979.05 |
29874.32 |
4% |
10 |
24905.27 |
4981.05 |
29886.32 |
16% |
25 |
24930.27 |
4986.05 |
29916.32 |
|
НСР-8218/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6223.82 |
1244.76 |
7468.58 |
4% |
10 |
6233.82 |
1246.76 |
7480.58 |
16% |
25 |
6258.82 |
1251.76 |
7510.58 |
|
НСР-8219/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
24895.27 |
4979.05 |
29874.32 |
4% |
10 |
24905.27 |
4981.05 |
29886.32 |
16% |
25 |
24930.27 |
4986.05 |
29916.32 |
|
НСР-8218/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
2252 |
| Ipilimumab |
EU/1/11/698/001 |
Yervoy, Concentrate for solution for infusion, 5 mg/ml-10 ml (50 mg), mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
6845.41 |
1369.08 |
8214.49 |
4% |
10 |
6855.41 |
1371.08 |
8226.49 |
16% |
25 |
6880.41 |
1376.08 |
8256.49 |
|
НСР-1792/25.11.2013 |
10.12.2013 |
10.12.2013 |
Неактивен |
2253 |
| Ipilimumab |
EU/1/11/698/002 |
Yervoy, Concentrate for solution for infusion, 5mg/ml-40 ml (200 mg) vial, mg, Pack: 1 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb S.r.l.,Италия |
27381.62 |
5476.32 |
32857.94 |
4% |
10 |
27391.62 |
5478.32 |
32869.94 |
16% |
25 |
27416.62 |
5483.32 |
32899.94 |
|
НСР-1792/25.11.2013 |
10.12.2013 |
10.12.2013 |
Неактивен |
2252 |
| Memantine |
20140328 |
Ymana, Film coated tablet, 10, mg, Pack: 28 |
Alkaloid – INT d.o.o., Словения |
Alkaloid-INT d.o.o., Slandrova ulica 4, 1231 Ljubljana-Crnuce, Словения |
20.75 |
4.15 |
24.9 |
6% |
1.25 |
22 |
4.4 |
26.4 |
18% |
3.74 |
25.74 |
5.15 |
30.89 |
|
НСР-8372/26.02.2016; НСР-12482/28.04.2017 |
13.05.2017 |
02.06.2017 |
Активен |
4194 |
| Memantine |
20140328 |
Ymana, Film coated tablet, 10, mg, Pack: 28 |
Alkaloid – INT d.o.o., Словения |
Alkaloid-INT d.o.o., Slandrova ulica 4, 1231 Ljubljana-Crnuce, Словения |
20.89 |
4.18 |
25.07 |
6% |
1.25 |
22.14 |
4.43 |
26.57 |
18% |
3.76 |
25.9 |
5.18 |
31.08 |
|
НСР-8372/26.02.2016 |
16.03.2016 |
16.03.2016 |
Неактивен |
4194 |
| Memantine |
20140330 |
Ymana, Film coated tablet, 20, mg, Pack: 28 |
Alkaloid – INT d.o.o., Словения |
Alkaloid-INT d.o.o., Slandrova ulica 4, 1231 Ljubljana-Crnuce, Словения |
38 |
7.6 |
45.6 |
4% |
1.52 |
39.52 |
7.9 |
47.42 |
16% |
6.08 |
45.6 |
9.12 |
54.72 |
|
НСР-8372/26.02.2016 |
16.03.2016 |
16.03.2016 |
Активен |
4203 |
| Trabectedin |
EU/1/07/417/002 |
YONDELIS, Powder for concentrate for solution for infusion, 1, mg, Pack: 1 |
Pharma Mar, S.A, Испания |
Pharma Mar, S.A., Madrid, Spain |
3232.77 |
646.55 |
3879.32 |
4% |
10 |
3242.77 |
648.55 |
3891.32 |
16% |
25 |
3267.77 |
653.55 |
3921.32 |
Отхвърлена жалба на Комисия по прозрачност КП-37/05.03.2015 ; Цената е заличена с решение НСР-6399/12.06.2015 (в сила от 16.07.2015 ) |
НСР-3074/21.03.2014 |
02.04.2015 |
02.04.2015 |
Заличен |
3652 |
| Trabectedin |
EU/1/07/417/002 |
YONDELIS, Powder for concentrate for solution for infusion, 1, mg, Pack: 1 |
Pharma Mar, S.A, Испания |
Pharma Mar, S.A., Madrid, Spain |
3282.29 |
656.46 |
3938.75 |
4% |
10 |
3292.29 |
658.46 |
3950.75 |
16% |
25 |
3317.29 |
663.46 |
3980.75 |
|
КЦРР-2602/14.03.2013. |
08.07.2013 |
08.07.2013 |
Неактивен |
3652 |
| Trabectedin |
EU/1/07/417/001 |
YONDELIS, Powder for concentrate for solution for infusion, 0.25, mg, Pack: 1 |
Pharma Mar, S.A, Испания |
Pharma Mar, S.A., Madrid, Spain |
872.44 |
174.49 |
1046.93 |
4% |
10 |
882.44 |
176.49 |
1058.93 |
16% |
25 |
907.44 |
181.49 |
1088.93 |
Цената е заличена с решение НСР-6400/12.06.2015 (в сила от 16.07.2015 ) |
КЦРР-2601/14.03.2013. |
08.07.2013 |
08.07.2013 |
Заличен |
1905 |
| Trabectedin |
EU/1/07/417/001 |
YONDELIS, Powder for concentrate for solution for infusion, 0.25, mg, Pack: 1 |
Pharma Mar, S.A, Испания |
Pharma Mar, S.A., Madrid, Spain |
992.19 |
198.44 |
1190.63 |
4% |
10 |
1002.19 |
200.44 |
1202.63 |
16% |
25 |
1027.19 |
205.44 |
1232.63 |
|
КЦ-2358/17.06.2011 |
02.07.2011 |
02.07.2011 |
Неактивен |
1905 |
| Trabectedin |
EU/1/07/417/002 |
YONDELIS, Powder for concentrate for solution for infusion, 1, mg, Pack: 1 |
Pharma Mar, S.A, Испания |
Pharma Mar, S.A., Madrid, Spain |
3733.29 |
746.66 |
4479.95 |
4% |
10 |
3743.29 |
748.66 |
4491.95 |
16% |
25 |
3768.29 |
753.66 |
4521.95 |
|
КЦ-2358/17.06.2011 |
02.07.2011 |
02.07.2011 |
Неактивен |
3652 |
| Bicalutamide |
20100846 |
YONISTIB, Film coated tablet, 50, mg, Pack: 28 |
Неола Фарма ЕООД, България |
Genepharm S.A., 18th klm Marathonos Avenue, 15351 Pallini Attikis, Гърция |
18.87 |
3.77 |
22.64 |
6% |
1.13 |
20 |
4 |
24 |
18% |
3.4 |
23.4 |
4.68 |
28.08 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-158/29.04.2015 |
НСР-4422/07.08.2014. |
16.05.2015 |
16.05.2015 |
Активен |
3848 |
| Bicalutamide |
20100846 |
YONISTIB, Film coated tablet, 50, mg, Pack: 28 |
Неола Фарма ЕООД, България |
Genepharm S.A., 18th klm Marathonos Avenue, 15351 Pallini Attikis, Гърция |
63.88 |
12.78 |
76.66 |
4% |
2.56 |
66.44 |
13.29 |
79.73 |
16% |
10.22 |
76.66 |
15.33 |
91.99 |
промяна на обстоятелства НСР-4769/13.10.2014 |
КЦРР-2828/20.03.2013 |
18.04.2013 |
18.04.2013 |
Неактивен |
3848 |
| Bicalutamide |
№ ІІ - 11653/22.12.2010 |
YONISTIB, Film coated tablet, 50, mg, Pack: 28 |
Ромастру Трейдинг ЕООД, България |
Genepharm S.A., 18th klm Marathonos Avenue, 15351 Pallini Attikis, Гърция |
71.88 |
14.38 |
86.26 |
4% |
2.88 |
74.76 |
14.95 |
89.71 |
16% |
11.5 |
86.26 |
17.25 |
103.51 |
|
КЦ-2177/21.04.2011 |
05.05.2011 |
05.05.2011 |
Неактивен |
3848 |
| Aflibercept |
EU/1/12/814/001 |
Zaltrap, Concentrate for solution for infusion, 25 mg/ml - 4 ml, mg, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
564.59 |
112.92 |
677.51 |
4% |
10 |
574.59 |
114.92 |
689.51 |
16% |
25 |
599.59 |
119.92 |
719.51 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-362/26.08.2016; промяна на обстоятелства НСР-9171/27.04.2016, НСР-9738/14.07.2016 |
НСР-8044/12.02.2016; НСР-9718/07.07.2016; НСР-16685/30.08.2018 |
14.09.2018 |
02.10.2018 |
Активен |
3320 |
| Aflibercept |
EU/1/12/814/001 |
Zaltrap, Concentrate for solution for infusion, 25 mg/ml - 4 ml, mg, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
565.67 |
113.13 |
678.8 |
4% |
10 |
575.67 |
115.13 |
690.8 |
16% |
25 |
600.67 |
120.13 |
720.8 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-362/26.08.2016; промяна на обстоятелства НСР-9171/27.04.2016, НСР-9738/14.07.2016 |
НСР-9718/07.07.2016 |
22.07.2016 |
02.08.2016 |
Неактивен |
3320 |
| Aflibercept |
EU/1/12/814/001 |
Zaltrap, Concentrate for solution for infusion, 25 mg/ml - 4 ml, mg, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
565.67 |
113.13 |
678.8 |
4% |
10 |
575.67 |
115.13 |
690.8 |
16% |
25 |
600.67 |
120.13 |
720.8 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-362/26.08.2016; промяна на обстоятелства НСР-9171/27.04.2016, НСР-9738/14.07.2016 |
НСР-8044/12.02.2016 |
02.07.2016 |
02.07.2016 |
Неактивен |
3320 |
| Aflibercept |
EU/1/12/814/003 |
Zaltrap, Concentrate for solution for infusion, 25 mg/ml - 8 ml, mg, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
1131.33 |
226.27 |
1357.6 |
4% |
10 |
1141.33 |
228.27 |
1369.6 |
16% |
25 |
1166.33 |
233.27 |
1399.6 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-362/26.08.2016; промяна на обстоятелства НСР-9171/27.04.2016, НСР-9738/14.07.2016 |
НСР-9720/07.07.2016 |
22.07.2016 |
02.08.2016 |
Активен |
3319 |